Creative Capital Management Investments’s Evogene EVGN Stock Holding History

Creative Capital Management Investments’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20	Closed	-$126	–	225
2023 Q1	$126	Hold	20	–	–	﹤0.01%	234
2022 Q4	$0	Buy	+20	New	+$141	﹤0.01%	216

Other funds holding EVGN

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

CAG

Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return

JIC

Joel Isaacson & Co New York $3.02B AUM 21.81% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Creative Capital Management Investments's EVGN Position: Q2 2023 in Review

Creative Capital Management Investments sold out of Evogene (EVGN) in Q2 2023, closing a stake of 20 shares — an estimated $126 sold.

Creative Capital Management Investments first reported a position in EVGN in Q4 2022 and held it in 2 quarters. The position peaked at $126 in Q1 2023. 28 funds tracked by Wall St. Rank hold EVGN as of Q2 2023.

Creative Capital Management Investments reported no remaining Evogene position as of Q2 2023 after selling out during the quarter.
Creative Capital Management Investments sold 20 Evogene shares in Q2 2023, an estimated $126.
Creative Capital Management Investments first reported a position in Evogene in Q4 2022 and held it in 2 quarters.
Creative Capital Management Investments's Evogene position peaked at $126 in Q1 2023.
28 funds tracked by Wall St. Rank held Evogene as of Q2 2023.

Based on Creative Capital Management Investments's 13F filing for Q2 2023, filed 25 Jul 2023.